Background: Reporting of relative risk reduction as the measure of treatment effect in randomized clinical trials (RCTs) may be difficult to understand. Here, we compare two methods for assessing absolute benefits of anticancer therapies.
introduction
In phase III randomized clinical trials (RCTs), the treatment effect of new anticancer therapies is usually reported in terms of relative benefit, e.g. using the ratio of hazards between treatment arms. Calculation of this hazards ratio (HR) implies an assumption that the HR between treatment arms remains constant with time (the assumption of proportional hazards) [1] . While HR may be a good indicator of relative benefit, reporting of absolute benefits can help to improve understanding of the clinical relevance of the treatment effect of new therapies. Despite relative and absolute benefits being expressions of the same clinical results, clinicians are more likely to endorse treatments based on the numerically more impressive values of relative benefits (e.g. HR) when compared with the numerically less impressive values of the absolute benefit (e.g. absolute difference in proportion alive at a given time) [2] [3] [4] [5] [6] [7] . Presenting the benefits of taking medical therapy as a relative benefit also increases the likelihood of patients accepting treatment compared with presenting absolute summary statistics [8] . However, the assumption of proportional hazards is sometimes inappropriate when Kaplan-Meier curves (hereafter curves) do not separate uniformly; reporting of treatment effect by HR in such situations may be inappropriate [9] . In situations such as this, one frequently used solution is to report the absolute benefit at a selected time point.
There is no established standard method for the assessment and reporting of absolute benefits. Usually, investigators report absolute benefits as a difference in the percentage of patients with or without a pre-defined event at specific times, such as 1-, 3-, or 5-year survival rates in early/localized cancer (i.e. absolute risk reduction), or the difference in median survival for trials evaluating treatment of advanced/metastatic cancer. Absolute differences in outcome at one point provide a limited measure of benefit [10] , hence some authors report absolute differences at multiple time points to better understand the results. Making proper inferences from these 'snapshot' measures are difficult as they do not relate directly to standard statistical testing. This is particularly apparent when assumptions about proportional hazards are violated and curves have unusual shapes, or the number of patients at risk becomes small.
Although absolute benefits are usually measured at one point, an alternative and perhaps superior measure of the absolute treatment effect can be calculated that uses all of the data. Tan and Murphy [11] proposed a statistic called the 'average duration of life gained' (ADLG) as a measure to summarize differences in treatment effect. When reported as life-years gained, ADLG is equal to the area between the curves when survival is plotted on a scale from zero to one and the follow-up is measured in years. The use of area between curves has been proposed as a more meaningful representation of the difference in survival that uses all of the available data [12] and is less susceptible to random variations due to small numbers of patients at risk. However, there is a bias in estimating the area between curves when large proportions of data are censored [13, 14] and area can be affected by a few long time to events (i.e. skewness in the data), which are common in RCTs evaluating cancer therapy. To reduce the effect of skewness in the data, one solution is to compute follow-up only to a certain time point.
In the present analysis, we evaluated systematically absolute benefits of investigational adjuvant medical therapies in RCTs of breast and colorectal cancer by two different methods: (i) as the difference between curves at pre-defined time points (snapshot method) and (ii) as the area between curves up to pre-defined time points divided by the whole graph area up to these same time points (area method). These methods would be interpreted as, e.g. at 3 years: (i) the difference in observed survival at 3 years and (ii) the observed area between curves by 3 years divided by the whole graph area by 3 years. We hypothesized that the area method would provide a more consistent measure of absolute benefit when compared with the snapshot method, especially when curves have unusual shapes, and the assumptions of proportional hazards are violated. We also aimed to compare absolute benefits determined as the difference in median survival between curves (snapshot method) with area between curves (area method) in RCTs evaluating new therapies for metastatic breast and colorectal cancer. Figure S1 , available at Annals of Oncology online). We felt that statistically significant results would ensure adequate separation of the survival curves and more reliable assessment of absolute benefits of investigational therapies. To generalize our results, we pre-planned an analysis of absolute benefits of medical therapies being investigated in patients with heart failure. We searched PubMed for the corresponding RCTs published between 1975 and 2009, which reported statistically significant results.
From reports of oncologic RCTs, we extracted curves, which presented graphical results for primary or secondary time-to-event end points: (i) overall survival (OS), (ii) event-free survival (EFS) [including disease-free survival (DFS) and relapse-free survival (RFS)], and (iii) progression-free survival (PFS) [including time to progression]. For EFS and PFS, different outcomes were grouped together even though there are some differences in end point definitions between trials. For trials evaluating treatments for metastatic disease, only mature paired curves that ultimately converged as all patients progressed or died were eligible for our analysis (supplementary Figure S1 , available at Annals of Oncology online). This ensured reliable assessment of area between curves. As composite time-to-event end points in RCTs of heart failure are often variably defined, we included into our analysis only RCTs, which demonstrated statistically significant results in OS.
data extraction
For the snapshot method, absolute benefits of experimental medical therapies were determined as: (i) the absolute difference between curves representing investigational and control therapy at three arbitrarily predetermined time points (i.e. 12, 36, and 60 months) in trials of adjuvant therapy and (ii) the absolute difference in median survival between curves in trials for metastatic disease. For the area method, absolute benefits were determined as: (i) the area between curves up to the three pre-determined time points and (ii) the area between curves for trials for metastatic disease. In adjuvant trials, the area between curves up to the pre-determined time point was divided by the whole graph area up to the same time point (Figure 1 ). This allowed us to directly compare absolute differences determined by the area method to those determined by the snapshot method. In contrast, in the metastatic setting both methods provide absolute differences in a unit of time (e.g. months) and no such adjustments were necessary. In RCTs evaluating new medical therapies in heart failure, we set time points at 6, 18, and 30 months to capture the largest amount of data. Absolute differences between curves at different time points were assessed manually and area between curves was estimated using the UN-SCAN-IT™ Graph Digitizing Software (Silk Scientific Inc., Orem, Utah, USA); absolute differences were always calculated as experimental minus the control arm.
Curves describing the results of adjuvant therapies were assessed visually by two independent investigators (BS and EA) to determine whether they met the assumptions of proportional hazards as described by Schemper et al. [16] . Curves were categorized as (i) proportional, (ii) converging, (iii) diverging, or (iv) crossing hazards. Due to small numbers in some groups, this was dichotomized into 'proportional hazards' (group a) versus 'nonproportional hazards' (groups b, c, and d). To evaluate inter-observer agreement, the assessments of the two authors were compared; disagreements were resolved by consensus.
statistical analysis
Descriptive statistics were used to summarize characteristics of eligible curves. For curves representing adjuvant therapies, analysis of absolute benefits was carried out separately for each pre-defined time point. The Pitman-Morgan test based on rank statistics was used to test for differences in variability [17] . Comparison of absolute benefits determined by the two methods was undertaken for each pair of survival curves and positive values indicate that the absolute benefit was larger when calculated by the snapshot method than when calculated by the area method. The Wilcoxon rank sum test was used to test whether estimates of differences in treatment effect by the two methods differed statistically from zero. The potential effect of proportional versus non-proportional hazards and tumor site was investigated using linear regression. For curves describing outcomes of therapy for metastatic disease descriptive statistics were used to summarize our findings.
All analyses were carried out in SAS v9.1 (SAS Institute, Cary, NC, USA). All tests were two-sided and a P-value of <0.05 was considered statistically significant. No adjustment for multiple analyses was carried out.
results search results and characteristics of RCTs and curves
We identified 83 pairs of curves from 65 eligible RCTs evaluating investigational adjuvant medical therapies and 39 pairs of curves from 37 RCTs evaluating investigational medical therapies for metastatic disease (Table 1 ). In the adjuvant setting, 30 curves presented OS data, of which 80% were for breast cancer, while 53 presented EFS data, of which 85% were for breast cancer. Inter-observer agreement in the assessment of proportional hazards for OS and EFS in RCTs for breast and colorectal cancer was good (kappa = 0.63 [95% CI 0.38-0.88]) and moderate (kappa = 0.44 [95% CI 0.19-0.69]), respectively. When disagreements were resolved 75% (n = 62) of survival curves satisfied visually the assumption of proportional hazards and 25% (n = 21) did not, including 4% (n = 3) which converged, 20% (n = 17) which diverged, and 1% (n = 1) which crossed (reviewers agreed on 68% [n = 42] and 90% [n = 19] of curves with proportional and non-proportional hazards, respectively). In metastatic disease, 34 pairs of curves presented the data for PFS, of which 53% were for breast cancer. Only five pairs of curves presented the data for OS (Table 1) . EFS, event-free survival (includes disease-free survival and relapse-free survival); PFS, progression-free survival (includes time to progression); OS, overall survival; RCTs, randomized clinical trials. Figure 1 . A description of methods used in the comparison of absolute benefits determined by both methods for adjuvant therapies and therapies in metastatic disease. For the snapshot method, absolute benefits of investigational medical therapies were determined as the absolute difference between curves representing investigational and control therapy at three arbitrarily pre-determined time points (i.e. 12, 36, and 60 months) in trials of adjuvant therapy and the absolute difference in median survival between curves in trials for metastatic disease. For the area method, absolute benefits were determined as the area between curves up to the three predetermined time points and the area between curves for trials for metastatic disease. In adjuvant trials, the area between curves up to the predetermined time point was divided by the whole graph area up to the same time point. Table 2 summarizes the median estimates and ranges of pooled absolute benefits determined by the snapshot and area methods at pre-defined time points. In the majority of trials, one arm was superior to the other arm at all time points evaluated. The median absolute benefit measured by both methods increased with follow-up time. There was also a statistically significant difference in the extent of variability between the different methods for estimating benefit in OS at 36 and 60 months, and for EFS at all time points: the absolute benefit measured by the snapshot method was more variable (Figure 2A and B) . Variability did not appear to depend on whether the curves satisfied the assumption of proportional hazards or not (supplementary Figure S2 , available at Annals of Oncology online).
The difference in estimates of absolute benefits determined by snapshot and area methods across trials was statistically significant, for each outcome and time point, with the exception of 12-month OS. In general, the snapshot method provided larger estimates of absolute benefit than those calculated by the area method (Table 2) . We further evaluated whether the difference in absolute benefits determined by the two methods depended on whether the assumption of proportional hazards holds and on site of disease. There was a weak trend to larger differences observed between methods when there was a violation of the assumption of proportional hazards at the time with the longest follow-up (supplementary Table S1 and Figure S2 , available at Annals of Oncology online).
analysis of absolute benefits in trials for metastatic disease
There appeared to be little difference between the area and snapshot methods in determining differences between curves evaluating new therapies for metastatic disease (Figure 3 , supplementary Figure S3 , available at Annals of Oncology online). In 62% (n = 24) and 71% (n = 28) of pairs of curves (for OS and PFS curves combined), the estimates of differences in OS or PFS between treatment arms for the snapshot and area methods were within 0.5 and 1 month of each other, respectively. The largest discrepancies between absolute benefits estimated by the two methods occurred when curves had unusual shapes.
analysis of absolute benefits for trials evaluating medical therapy in heart failure
To generalize our data, we also analyzed 22 curves presenting OS data from RCTs evaluating medical therapies in patients with heart failure. Similar to cancer trials, the snapshot method was associated with larger estimates of absolute benefit when compared with the area method. However, we were not able to demonstrate increased variability in estimates of absolute benefit determined by the snapshot method with an increasing follow-up, likely due to lack of data at times with the longest follow-up (supplementary Table S2 , available at Annals of Oncology online).
discussion
Reporting of relative benefits of investigational anticancer therapies is difficult for some health professionals and patients EFS, event-free survival (includes disease-free survival and relapse-free survival); OS, overall survival; RCTs, randomized clinical trials.
a Based on the Pitman-Morgan test, which is a test for differences in variability between two correlated outcomes where each outcome follows a normal distribution. In our analysis, we compared whether the variance of the outcome 1 (absolute benefits determined by snapshot method) equals the variance of outcome 2 (absolute benefits determined by area method).
b
Based on Wilcoxon rank sum test, which is a non-parametric test for assessing whether one of the samples of independent observations tend to have larger values than the other.
to interpret correctly [2] [3] [4] [5] [6] [7] [8] . Furthermore, reporting of relative benefits may be inappropriate when curves have unusual shapes and the assumption of proportional hazards is violated.
Reporting of absolute benefits of new anticancer therapies is important because it allows presentation of the treatment effect in RCTs in a way that is more easily understood by patients, practitioners, and policy makers. Here, we compared the use of snapshot and area methods in the assessment of absolute benefits in RCTs for people with breast and colorectal cancer. We found that in RCTs evaluating adjuvant therapies, the area method provides a more consistent measure of absolute benefit when compared with the snapshot method (i.e. variability between absolute treatment effects over the follow-up period is less for the area method than the snapshot method), This finding was observed irrespective of whether the assumption about proportional hazards holds. In the metastatic setting, the snapshot and area methods give similar estimates of the absolute benefit in a substantial proportion of paired curves, although the area method may allow a more valid estimate of the absolute benefit when the curves have unusual shapes. In RCTs evaluating adjuvant medical therapies assessment of absolute benefits in breast and colorectal cancer determined by both the snapshot and area methods increased with longer follow-up time. Pooled median absolute benefits determined by the snapshot method at 36 and 60 months were on average 1.6-fold larger than those determined by the area method, but from this alone it is not possible to conclude which method is better. Absolute benefits determined at pre-defined time points by the snapshot method were also more variable, particularly as the number of patients at risk decreased with an increasing follow-up (Table 2, Figure 2A and B). Furthermore, differences between absolute benefits in OS determined by both methods increased with the duration of follow-up (Table 2 ). This may be particularly relevant when absolute benefits of new therapies are assessed in settings with late events (e.g. hormone receptorpositive breast cancer) and less in settings with early events (e. g. triple negative or HER-2 positive breast cancer and colorectal cancer).
When proportional hazards are violated and curves have unusual shapes, absolute benefits determined at one point may not be representative of benefit from the new therapy (supplementary Figure S4 , available at Annals of Oncology online). In this study, it was observed in this situation that the two methods gave a trend for more divergent results, but this difference was not statistically significant (supplementary Table S1 and Figure S2 , available at Annals of Oncology online). Besides limited statistical power due to a small sample of curves, inter-observer agreement in evaluating survival curves for proportional hazards was only moderate to good, and our results related to proportional hazards should therefore be interpreted cautiously.
When comparing estimates of absolute benefits by the snapshot and area methods in RCTs evaluating investigational medical therapies for metastatic disease, we found that both methods gave similar estimates in 62% of cases. Of note, only mature paired curves, which ultimately joined were eligible for our analysis. We noted that the largest discrepancies occurred when curves had unusual shapes [18, 19] , not the typical 'banana' shape which is frequently seen in the metastatic Distribution of data for snapshot and area methods for (A) overall survival (OS) and (B) event-free survival outcomes in randomized clinical trials evaluating adjuvant therapy for breast and colorectal cancer. Absolute benefits determined by snapshot method were numerically larger and also more variable. For example, in the study by Love et al. [23] , absolute benefits of experimental treatment in OS at 12, 36, and 60 months were 2.4%. 4.8%, and 7.2% when determined by the snapshot method and 0.2%, 3.1%, and 3.5% when determined by the area method. Boxes represent 25th and 75th percentiles, error bars represent SD and circles represent statistical outliers. setting. Therefore, the area between curves may be an acceptable measure of absolute benefit of new therapies when curves have unusual shapes. For example, Van Cutsem et al. [18] recently reported the area between curves as a measure of absolute benefit of panitumumab when compared with placebo for the treatment of metastatic colorectal cancer. Furthermore, when curves are poorly defined at the longer follow-up measurement of area with a horizontal cut-off at 50% or 20% survival might be a reasonable alternative to the reported absolute treatment effect. Our analysis has several limitations. First, this was a pooled analysis of published results from RCTs and we estimated absolute benefits from curves. Absolute benefits for time-toevent end points are more accurate when calculated directly from raw data [20] . Estimation of the area between survival curves by different software packages has not been compared, so it is possible that different results might have been obtained if a different software package was used. Secondly, RCTs included in our analysis were conducted in different time periods and are heterogeneous. As the sample sizes of RCTs in oncology have increased, the absolute benefits of new therapies have decreased over time [15, 21] . Also, absolute benefits from earlier RCTs might be less variable with an increased follow-up when compared with contemporary RCTs. Our analysis will be influenced by censoring of patients: censoring may be influenced by sample size, and also by duration of follow-up, which is likely to be shorter in more recent trials. Stopping RCTs early for benefit may overestimate treatment effect in RCTs, especially in those with small sample size [22] . Thirdly, inclusion of only curves reporting statistical significance may introduce the bias as statistical testing relates to relative differences, which are the primary outcome measures in almost all of the trials, and not to absolute differences. Finally, on the basis of published data, we were not able to provide a variability measure of pooled absolute benefits. The identification of such a measure should be an objective for future research on this topic.
In summary, having a reliable measure of absolute benefit can greatly improve the ability to understand the true treatment effect when used in conjunction with the measure of relative benefit. The area method provides an alternative measure of the absolute treatment effect, which uses all of the available data, is less dependent on the shape of survival curves and might be advantageous.
